{"id":390556,"date":"2026-07-29T13:24:23","date_gmt":"2026-07-29T13:24:23","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-tx\/390556\/"},"modified":"2026-07-29T13:24:23","modified_gmt":"2026-07-29T13:24:23","slug":"forte-biosciences-acquired-by-dutch-pharma-firm-for-2-2b-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-tx\/390556\/","title":{"rendered":"Forte Biosciences Acquired by Dutch Pharma Firm for $2.2B \u00bb Dallas Innovates"},"content":{"rendered":"

\"\"<\/p>\n

Dutch biopharma Argenx is acquiring Dallas-based Forte Biosciences for $2.2 billion. [Image: AdobeStock]<\/p>\n

Dallas-based biopharmaceutical company Forte Biosciences Inc. has been acquired by Netherlands pharmaceutical company Argenx for $2.2 billion, the companies announced. Argenx CEO Karen Massey said in a statement that Forte\u2019s experimental drug FB102 will add to the company\u2019s ambition of being the \u201cleading immunology innovator of the future.\u201d<\/p>\n

From Dallas startup to acquisition target<\/p>\n

Forte was founded in 2017<\/a> by Paul A. Wagner,<\/a> who serves as the company\u2019s chairman and CEO. The company raised $150 million in a public stock offering<\/a> in April, after reporting a loss of $69 million<\/a> in 2025.<\/p>\n

In an early-stage clinical trial earlier this month, FB102 showed positive results<\/a> in treating vitiligo<\/a>. The autoimmune disease causes depigmentation, or white patches, on a patient\u2019s skin.<\/p>\n

The drug also showed positive results<\/a> in a clinical trial last year for treatment of celiac disease<\/a>. The autoimmune condition causes the body\u2019s immune system to attack gluten in the digestive tract. That reaction leads to inflammation and damage in the small intestine.<\/p>\n

What the companies are saying<\/p>\n

\u201cWe are incredibly proud of what we have achieved in advancing FB102 through clinical development and firmly believe that Argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody across a broad range of autoimmune diseases,\u201d Wagner said in a statement.<\/p>\n

Argenx says FB102 has the \u201cpotential to address multiple autoimmune diseases\u201d and fits with its approach of advancing treatments for diseases \u201cthat have lacked meaningful innovation for decades.\u201d<\/p>\n

The drug \u201ccomplements Argenx\u2019s existing portfolio\u201d of antibody-based programs, which includes autoimmune drug Vyvgart.<\/p>\n

\u201cThe addition of FB102 to our portfolio aligns perfectly with the Argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need,\u201d Massey said.<\/p>\n

Both companies\u2019 boards of directors have approved the deal, which is expected to close in the third quarter.<\/p>\n

More on Forte Biosciences<\/p>\n

Forte, headquartered at Dallas\u2019 Pegasus Park, announced a $53 million private placement<\/a> from leading healthcare investors in November 2024 to support FB102\u2019s continued clinical development.<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n

\t\"\"<\/a><\/p>\n

As chairman, outgoing CEO Ken Pedersen will concentrate on board leadership and overall strategy while incoming CEO Kyle Carter and the executive team oversee day-to-day operations, the Dallas- based company said. Carter has been with Zenylitics since its founding, providing leadership in customer acquisition, client delivery, and the development of the company’s capabilities in India.<\/p>\n

With a background in U.S. intelligence, Joel Molinoff recently served as global head of third-party risk products and services at BlueVoyant, where he guided the development and growth of the company\u2019s third-party risk management business serving commercial and government clients around the world, Dallas-based iCOUNTER said.<\/p>\n

\t\"\"<\/a><\/p>\n

Located in Trammell Crow Center, Equiton’s new office was “carefully selected for its location in one of America’s premier financial hubs,” where some of the nation’s leading financial institutions have established major operations serving clients across the country, the firm said.<\/p>\n

\t\"\"<\/a><\/p>\n

Founded in 2000 with offices in Las Colinas and Mexico City, Legion Advertising has developed a strong track record of helping brands connect authentically with diverse audiences\u2014particularly within the U.S. Hispanic market. Now it will do that with Fernando S\u00e1nchez Servitje at the helm.<\/p>\n

Fortium’s acquisition brings a leading player in the interim technology market into ZRG’s platform and gives clients access to proven CIO, CTO, and CISO leadership on demand.<\/p>\n

\t\"\"<\/a><\/p>\n

With its proposed acquisition of Dallas Capital Bank, MidFirst\u2014the nation’s largest privately owned bank\u2014is adding to a growing Texas footprint which already includes banking locations in Dallas, San Antonio, and Houston.<\/p>\n","protected":false},"excerpt":{"rendered":"Dutch biopharma Argenx is acquiring Dallas-based Forte Biosciences for $2.2 billion. [Image: AdobeStock] Dallas-based biopharmaceutical company Forte Biosciences…\n","protected":false},"author":2,"featured_media":390557,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[137589,137590,102,104,103,137591,137592,137593,137594],"class_list":["post-390556","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dallas","tag-argenx","tag-celiac-disease","tag-dallas","tag-dallas-headlines","tag-dallas-news","tag-forte-biosciences","tag-karen-massey","tag-paul-wagner","tag-vitiligo"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/390556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/comments?post=390556"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/390556\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media\/390557"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media?parent=390556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/categories?post=390556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/tags?post=390556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}